These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 20435227)

  • 21. Refining the use of warfarin through genetic testing.
    Lee SC
    Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287
    [No Abstract]   [Full Text] [Related]  

  • 22. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the pharmacogenetic approach to warfarin dosing.
    Glurich I; Burmester JK; Caldwell MD
    Heart Fail Rev; 2010 May; 15(3):239-48. PubMed ID: 18998206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacogenomics of warfarin and clopidogrel.
    Shin J
    J Pharm Pract; 2012 Aug; 25(4):428-38. PubMed ID: 22674970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
    Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
    Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
    Moreau C; Siguret V; Loriot MA
    Rev Med Interne; 2010 May; 31(5):361-8. PubMed ID: 20362363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of genetic factors for warfarin dose prediction.
    Caldwell MD; Berg RL; Zhang KQ; Glurich I; Schmelzer JR; Yale SH; Vidaillet HJ; Burmester JK
    Clin Med Res; 2007 Mar; 5(1):8-16. PubMed ID: 17456829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
    Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A
    J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants.
    Wijnen PA; Linssen CF; Haenen GR; Bekers O; Drent M
    Mol Diagn Ther; 2010 Feb; 14(1):23-30. PubMed ID: 20121287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic predisposition to adverse drug reactions in the intensive care unit.
    Empey PE
    Crit Care Med; 2010 Jun; 38(6 Suppl):S106-16. PubMed ID: 20502164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
    Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
    Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical applicability of sequence variations in genes related to drug metabolism.
    Stojiljkovic M; Patrinos GP; Pavlovic S
    Curr Drug Metab; 2011 Jun; 12(5):445-54. PubMed ID: 21453274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.